Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 92Breast Neoplasms 85Neoplasms 79Prostatic Neoplasms 50Lung Neoplasms 43Neoplasm Metastasis 40Colorectal Neoplasms 37Leukemia, Myeloid, Acute 32Pain 27Head and Neck Neoplasms 25Colonic Neoplasms 25Multiple Myeloma 24Ovarian Neoplasms 23Lymphoma 23Carcinoma, Hepatocellular 23Pancreatic Neoplasms 22Lymphoma, Follicular 21Melanoma 20Leukemia 20Rectal Neoplasms 19Lymphoma, Non-Hodgkin 19Urinary Bladder Neoplasms 17Recurrence 17Stomach Neoplasms 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Squamous Cell Carcinoma of Head and Neck 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leiomyoma 13Brain Neoplasms 13

Interventions

enzalutamide 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Patient Preference × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡